Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
Status:
Recruiting
Trial end date:
2022-05-05
Target enrollment:
Participant gender:
Summary
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib
and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the
first-line treatment.